CATs™

ASO has evolved from the 1st to 3rd generation modified ASO technologies and has progressed to target delivery ASOs for organs other than livers or kidneys.
CATs™ (Conjugated ASO Targeting Solution) is Autotelic Bio's platform technology, which enables the derivation of novel molecules
by utilizing conjugate techniques between antibodies, peptides, and ASOs to reduce side effects and increase efficacy.